4.5 Article

Role of surgical resection in colorectal lung metastases: analysis of 137 patients

期刊

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
卷 26, 期 2, 页码 183-190

出版社

SPRINGER
DOI: 10.1007/s00384-010-1075-6

关键词

Colorectal carcinoma; Lung metastases; Lung metastasectomy; Prognosis

向作者/读者索取更多资源

The aim of this study is to investigate clinicopathologic characteristics and to identify prognostic factors in patients undergoing pulmonary metastasectomy for colorectal carcinoma. This study is a single-institution retrospective study of 137 consecutive patients who underwent 158 pulmonary resections for metastatic colorectal carcinoma between January 1989 and June 2008. Median disease-free interval between colorectal resection and pulmonary metastasectomy was 35.6 months (range, 0.6 to 154.3 months). No perioperative deaths occurred. Follow-up was 100% complete and mean follow-up was 41.6 +/- 27.6 months. Median survival was 36.2 months (range, 4.6 to 126 months). Overall 5- and 10-year survival rates were 55.4% and 30.8%, respectively, after pulmonary metastasectomy. At univariate analysis of patient survival, number of lung metastases (p = 0.002), disease-free interval of more than 24 month (p = 0.013), and absence of residual tumor (p = 0.024) were significant prognostic factors. At multivariate analysis, presence of solitary lung metastasis and disease-free interval of more than 24 months remained significant prognostic factors. There was no significant difference in the 5-year survival for 121 patients undergoing single thoracotomy compared with 16 patients undergoing repeated resection(s) for recurrent colorectal lung metastasis (55.1% vs 59.5%; p = 0.79). Nor was the presence of hepatic metastasis associated with lower outcome (p = 0.77). Disease-free interval and number of metastases are the most significant prognostic factors for survival after pulmonary metastasectomy for colorectal carcinoma. Recurrent pulmonary disease can benefit from repeated resection. Prior hepatectomy for liver involvement does not influence survival.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment

Chiara Riganti, Marcello Francesco Lingua, Iris Chiara Salaroglio, Chiara Falcomata, Luisella Righi, Deborah Morena, Francesca Picca, Daniele Oddo, Joanna Kopecka, Monica Pradotto, Roberta Libener, Sara Orecchia, Paolo Bironzo, Valentina Comunanza, Federico Bussolino, Silvia Novello, Giorgio Vittorio Scagliotti, Federica Di Nicolantonio, Riccardo Taulli

ONCOIMMUNOLOGY (2018)

Article Oncology

FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report

Clizia Zichi, Marco Tampellini, Marcello Tucci, Cristina Sonetto, Chiara Baratelli, Maria P. Brizzi, Giorgio V. Scagliotti

BMC CANCER (2018)

Article Oncology

Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal

Giuseppe Pelosi, Mauro Papotti, Luisella Righi, Giulio Rossi, Stefano Ferrero, Silvano Bosari, Fiorella Calabrese, Izidor Kern, Patrick Maisonneuve, Angelica Sonzogni, Adriana Albini, Sergio Harari, Fausto Barbieri, Enrica Capelletto, Anna Maria Catino, Domenica Cavone, Angela De Palma, Nicola Fusco, Francesca Lunardi, Eugenio Maiorano, Andrea Marzullo, Silvia Novello, Nikolaos Papanikolaou, Giulia Pasello, Antonio Pennella, Federica Pezzuto, Alessandra Punzi, Elena Prisciandaro, Federico Rea, Lorenzo Rosso, Anna Scattone, Gabriella Serio

JOURNAL OF THORACIC ONCOLOGY (2018)

Article Oncology

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma

Namrata S. Patil, Luisella Righi, Hartmut Koeppen, Wei Zou, Stefania Izzo, Federica Grosso, Roberta Libener, Marco Loiacono, Valentina Monica, Consuelo Buttigliero, Silvia Novello, Priti S. Hegde, Mauro Papotti, Marcin Kowanetz, Giorgio V. Scagliotti

JOURNAL OF THORACIC ONCOLOGY (2018)

Article Oncology

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Joanna Kopecka, Iris C. Salaroglio, Luisella Righi, Roberta Libener, Sara Orecchia, Federica Grosso, Vladan Milosevic, Preeta Ananthanarayanan, Luisa Ricci, Enrica Capelletto, Monica Pradotto, Francesca Napoli, Massimo Di Maio, Silvia Novello, Menachem Rubinstein, Giorgio V. Scagliotti, Chiara Riganti

LUNG CANCER (2018)

Article Multidisciplinary Sciences

Human renal angiomyolipoma cells of male and female origin can migrate and are influenced by microenvironmental factors

Francesca Bertolini, Giulia Casarotti, Luisella Righi, Enrico Bollito, Carlo Albera, Silvia Anna Racca, Donato Colangelo, Barbara Mognetti

PLOS ONE (2018)

Article Oncology

Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes

Marta Betti, Anna Aspesi, Daniela Ferrante, Marika Sculco, Luisella Righi, Dario Mirabelli, Francesca Napoli, Milena Rondon-Lagos, Elisabetta Casalone, Francesca Vignolo Lutati, Paola Ogliara, Paolo Bironzo, C. Laura Gironi, Paola Savoia, Antonella Maffe, Silvana Ungari, Federica Grosso, Roberta Libener, Renzo Boldorini, Michele Valiante, Barbara Pasini, Giuseppe Matullo, Giorgio Scagliotti, Corrado Magnani, Irma Dianzani

GENES CHROMOSOMES & CANCER (2018)

Review Oncology

Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective

Umberto Malapelle, Sara Pilotto, Francesco Passiglia, Francesco Pepe, Pasquale Pisapia, Luisella Righi, Angela Listi, Paolo Bironzo, Lorenzo Belluomini, Fabrizio Tabbo, Maria Lucia Reale, Gianluca Russo, Caterina De Luca, Silvia Novello, Giancarlo Troncone

Summary: Efforts have been made to optimize detection and clinical management of EGFR mutations in NSCLC, with a shift towards comprehensive detection platforms and new generation tyrosine kinase inhibitors targeting both common and uncommon mutations. Implementing these advances in routine practice remains critical, as it has the potential to impact long-term survival and quality of life for patients.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Review Oncology

Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma

Francesca Napoli, Angela Listi, Vanessa Zambelli, Gianluca Witel, Paolo Bironzo, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi

Summary: The tumor immune microenvironment plays a crucial role in the growth and progression of malignant pleural mesothelioma. Understanding the pathological characteristics of this microenvironment can lead to the discovery of new biomarkers and the development of advanced therapeutic strategies for this aggressive disease.

CANCERS (2021)

Review Oncology

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Virginia Liberini, Annapaola Mariniello, Luisella Righi, Martina Capozza, Marco Donatello Delcuratolo, Enzo Terreno, Mohsen Farsad, Marco Volante, Silvia Novello, Desiree Deandreis

Summary: Lung cancer, especially non-small cell lung cancer, remains a primary cause of cancer-related death. New therapeutic approaches, including immunotherapy, have shown significant improvement in patient survival and quality of life. However, the identification of predictive biomarkers is crucial to determine which patients will benefit most from immunotherapy-based treatments.

CANCERS (2021)

Article Oncology

Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response

Paolo Bironzo, Luca Primo, Silvia Novello, Luisella Righi, Silvana Candeloro, Lorenzo Manganaro, Federico Bussolino, Fabrizio Pirri, Giorgio V. Scagliotti

Summary: The aim of this study is to develop a technological platform for precision medicine, which includes comprehensive analysis and predictive algorithms based on the collection of lung cancer samples and patient biological information, to provide personalized diagnosis and treatment for patients.

CLINICAL LUNG CANCER (2022)

Article Cell Biology

Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer

Annapaola Mariniello, Fabrizio Tabbo, Davide Indellicati, Martina Tesauro, Nicole Alessia Rezmives, Maria Lucia Reale, Angela Listi, Enrica Capelletto, Simona Carnio, Valentina Bertaglia, Caterina Mecca, Lorena Consito, Marco De Filippis, Maristella Bungaro, Chiara Paratore, Massimo Di Maio, Francesco Passiglia, Luisella Righi, Dario Sangiolo, Silvia Novello, Massimo Geuna, Paolo Bironzo

Summary: This study explored and compared T cell characteristics in broncho-alveolar lavage (BAL) from tumor affected and contralateral lung, as well as matched peripheral blood (PB), in lung cancer patients. The results showed that T cells in BAL from advanced lung cancer patients presented features of exhaustion, which could be potential biomarkers for cancer immunotherapy outcome.
Review Pathology

What's new in mesothelioma

V Ascoli, B. Murer, A. Nottegar, C. Luchini, R. Carella, F. Calabrese, F. Lunardi, I Cozzi, L. Righi

PATHOLOGICA (2018)

Review Oncology

Classification of pulmonary neuroendocrine tumors: new insights

Giuseppe Pelosi, Angelica Sonzogni, Sergio Harari, Adriana Albini, Enrica Bresaola, Caterina Marchio, Federica Massa, Luisella Righi, Gaia Gatti, Nikolaos Papanikolaou, Namrata Vijayvergia, Fiorella Calabrese, Mauro Papotti

TRANSLATIONAL LUNG CANCER RESEARCH (2017)

Article Oncology

Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy

P. Boffetta, L. Righi, C. Ciocan, C. Pelucchi, C. La Vecchia, C. Romano, M. Papotti, E. Pira

ANNALS OF ONCOLOGY (2018)

暂无数据